Chiesi Farmaceutici S.p.A, an international, research-focused biopharmaceuticals and healthcare group, and Haisco Pharmaceutical Group Co. Ltd entered a licensing agreement to develop, manufacture, and commercialize outside China and adjacent territories (Hong Kong SAR, Macau SAR, and Taiwan District) HSK31858, a novel, reversible dipeptidyl peptidase 1 (DPP1) inhibitor for respiratory diseases. With this agreement, Chiesi will expand its product portfolio in its strategic respiratory field, ...